AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion, in a deal designed to bolster the buyer’s pipeline with an atopic dermatitis (AD) candidate set to advance to Phase III trials ...

Mice that were nursed on TVA-enriched milk responded faster to infections with viruses or common bacteria, even into adulthood.

Researchers say the discovery is unexpected because prions are usually discussed in the context of misfolding, aggregation, and brain disease—not immunity or antibiotic discovery.

The prevalence of autism spectrum disorder (ASD) is roughly one in 36 people, with a male-to-female ratio of 4:1. The disorder is known to be influenced by multiple factors, both genetic (gene ...

Merck & Co. will partner with Protillion Biosciences to discover multiple new therapy candidates, through a collaboration ...

A second positive Phase III data readout in two months is a major reason why Intellia Therapeutics shares have soared more than 76% over the past six months—including a 29% surge this past week that ...

Engineered extracellular vesicles delivering full-length DMD mRNA restored dystrophin and improved muscle strength and ...

A new study presents a fluorescence imaging-based technique to measure the activity rates of individual scramblase proteins.

Antimicrobial resistance (AMR) is a significant global health threat, with its impact felt across all regions of the world.

Researchers say results present “a concrete target to test whether changing how cocaine is metabolized can blunt the drive ...

The funds will be used to advance programs in Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease in ...

GlaxoSmithKline (GSK) has agreed to acquire Nuvalent for $10.6 billion, the companies said, in a deal designed to strengthen ...